Elucid Stock

Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.

Sign up today and learn more about Elucid Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Elucid Stock

Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Funding History

August 2013$375K
March 2014$1.4M
January 2016$1.0M
June 2016$3.0M
August 2016$4.0M
June 2019$3.0M
May 2021$10.0M
June 2022$27.0M

Management

President and CTO

Andrew J. Buckler

CCO

Jason Bottiglieri

Chief Commercial Officer

Scott Burger

Chief Medical Officer

Joins Elucid

CEO

Blake Richards

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo